Your browser doesn't support javascript.
loading
Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment.
Kamal, Mohamed A; Brennan, Barbara J; Subramoney, Vishak; Lien, Yi Ting Kayla; Morcos, Peter N; Frey, Nicolas; Rayner, Craig R.
Afiliación
  • Kamal MA; Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA.
  • Brennan BJ; Roche Translational and Clinical Research Center, Inc., New York, NY, USA.
  • Subramoney V; Roche Translational and Clinical Research Center, Inc., New York, NY, USA.
  • Lien YT; Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA.
  • Morcos PN; Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA.
  • Frey N; Pharma Research and Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Rayner CR; d3 Medicine LLC, Parsippany, NJ, USA.
Clin Pharmacol Drug Dev ; 4(5): 326-36, 2015 09.
Article en En | MEDLINE | ID: mdl-27137141

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Gripe Humana / Oseltamivir / Inhibidores de Glicósido Hidrolasas / Riñón / Enfermedades Renales / Neuraminidasa Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Pharmacol Drug Dev Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Gripe Humana / Oseltamivir / Inhibidores de Glicósido Hidrolasas / Riñón / Enfermedades Renales / Neuraminidasa Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Pharmacol Drug Dev Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos